[go: up one dir, main page]

MX2010001733A - Compustos de imidazo[1,2-a]pirazina para tratamiento de infecciones virales tales como hepatitis. - Google Patents

Compustos de imidazo[1,2-a]pirazina para tratamiento de infecciones virales tales como hepatitis.

Info

Publication number
MX2010001733A
MX2010001733A MX2010001733A MX2010001733A MX2010001733A MX 2010001733 A MX2010001733 A MX 2010001733A MX 2010001733 A MX2010001733 A MX 2010001733A MX 2010001733 A MX2010001733 A MX 2010001733A MX 2010001733 A MX2010001733 A MX 2010001733A
Authority
MX
Mexico
Prior art keywords
compounds
imidazopyrazine compounds
formula
imidazopyrazine
cvb
Prior art date
Application number
MX2010001733A
Other languages
English (en)
Inventor
Clifford John Harris
Dale Robert Mitchell
Angus Macleod
Nicholas John Palmer
Michael Daniel Goldsmith
Christophe Claude Parsy
Original Assignee
Biofocus Dpi Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biofocus Dpi Ltd filed Critical Biofocus Dpi Ltd
Publication of MX2010001733A publication Critical patent/MX2010001733A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a nuevos compuestos de imidazopirazina que tienen una fórmula representada por la siguiente fórmula (l) Los compuestos pueden ser preparados como composiciones farmacéuticas, y pueden ser utilizados para la prevención y el tratamiento de una infección viral, en particular una infección por VHC, HRV, Sb, y/o CVB en un paciente que tenga la necesidad del mismo.
MX2010001733A 2007-08-21 2008-08-20 Compustos de imidazo[1,2-a]pirazina para tratamiento de infecciones virales tales como hepatitis. MX2010001733A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0716292.8A GB0716292D0 (en) 2007-08-21 2007-08-21 Imidazopyrazine compounds
PCT/EP2008/060896 WO2009024585A2 (en) 2007-08-21 2008-08-20 Imidazo [1,2-a] pyrazine compounds for treatment of viral infections such as hepatitis

Publications (1)

Publication Number Publication Date
MX2010001733A true MX2010001733A (es) 2010-07-06

Family

ID=38566736

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010001733A MX2010001733A (es) 2007-08-21 2008-08-20 Compustos de imidazo[1,2-a]pirazina para tratamiento de infecciones virales tales como hepatitis.

Country Status (20)

Country Link
US (1) US8362018B2 (es)
EP (2) EP2567960A3 (es)
JP (1) JP2010536825A (es)
KR (1) KR20100081294A (es)
CN (1) CN101835780B (es)
AU (1) AU2008290531A1 (es)
BR (1) BRPI0815717A2 (es)
CA (1) CA2707521A1 (es)
CY (1) CY1113872T1 (es)
DK (1) DK2193131T3 (es)
ES (1) ES2404415T3 (es)
GB (1) GB0716292D0 (es)
HR (1) HRP20130202T1 (es)
MX (1) MX2010001733A (es)
NZ (1) NZ584108A (es)
PL (1) PL2193131T3 (es)
PT (1) PT2193131E (es)
SI (1) SI2193131T1 (es)
WO (1) WO2009024585A2 (es)
ZA (1) ZA201002009B (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0716292D0 (en) * 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
EP2285783B1 (en) 2008-04-29 2014-05-21 Boehringer Ingelheim International GmbH Indazole compounds as ccr1 receptor antagonists
CA2722811C (en) 2008-05-06 2016-07-05 Boehringer Ingelheim International Gmbh Pyrazole compounds as ccr1 antagonists
AP2739A (en) 2008-09-26 2013-09-30 Boehringer Ingelheim Int Azaindazole compounds as CCRI receptor antagonists
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
SI2491028T1 (sl) 2009-10-21 2014-03-31 Boehringer Ingelheim International Gmbh Indazolne in pirazolopiridinske spojine kot antagonisti receptorja CCR1
WO2011056440A1 (en) 2009-10-27 2011-05-12 Boehringer Ingelheim International Gmbh Heterocyclic compounds as ccr1 receptor antagonists
CA2778949C (en) 2009-10-30 2018-02-27 Janssen Pharmaceutica Nv Imidazo[1,2-b]pyridazine derivatives and their use as pde10 inhibitors
EP2509952A1 (en) * 2009-12-08 2012-10-17 Boehringer Ingelheim International GmbH Process for synthesis of intermediates useful for making substituted indazole and azaindazole compounds
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
CA2793279A1 (en) * 2010-03-18 2011-09-22 Ulrich Klar Imidazopyrazines
JP5793182B2 (ja) 2010-04-30 2015-10-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ１受容体アンタゴニストとしてのアザインダゾールアミド化合物
US9199999B2 (en) 2010-06-01 2015-12-01 Bayer Intellectual Property Gmbh Substituted imidazopyrazines
EP2651948A1 (en) * 2010-12-17 2013-10-23 Bayer Intellectual Property GmbH Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment hyperproliferative disorders
EP2651946B1 (en) * 2010-12-17 2015-05-27 Bayer Intellectual Property GmbH 2-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
EP2651945A1 (en) 2010-12-17 2013-10-23 Bayer Intellectual Property GmbH 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
WO2012080228A1 (en) 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft 6-thio-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
US9284317B2 (en) * 2010-12-17 2016-03-15 Bayer Intellectual Property Gmbh Substituted imidazo[1,2-a]pyrazines as MPS-1 inhibitors
EP2651950A1 (en) 2010-12-17 2013-10-23 Bayer Intellectual Property GmbH 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
JP5684406B2 (ja) 2010-12-23 2015-03-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ１受容体アンタゴニストとしてのピラゾロピペリジン化合物
GB201109763D0 (en) * 2011-06-10 2011-07-27 Ucl Business Plc Compounds
AU2012277912B2 (en) 2011-06-27 2017-03-23 Janssen Pharmaceutica Nv 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives
JPWO2013061962A1 (ja) * 2011-10-24 2015-04-02 武田薬品工業株式会社 二環性化合物
CA2872216C (en) 2012-06-26 2021-07-20 Janssen Pharmaceutica Nv Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl-[1,2,4] triazolo [4,3-a] quinoxaline compounds and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders
CN104411314B (zh) 2012-07-09 2017-10-20 詹森药业有限公司 磷酸二酯酶10的抑制剂
US9586949B2 (en) 2015-02-09 2017-03-07 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
LT3288940T (lt) 2015-04-29 2021-05-10 Janssen Pharmaceutica Nv Azabenzimidazolai ir jų panaudojimas kaip ampa receptoriaus moduliatorių
EP3288945B1 (en) * 2015-04-29 2019-09-18 Janssen Pharmaceutica NV Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators
BR112017026061B1 (pt) * 2015-06-24 2023-03-28 Curovir Ab Composto, composição farmacêutica, e, uso de um composto
JP6507976B2 (ja) * 2015-09-30 2019-05-08 東レ株式会社 イミダゾール−２−カルボン酸エステル誘導体又はその塩の製造方法
LT3371190T (lt) 2015-11-06 2022-08-10 Incyte Corporation Heterocikliniai junginiai, kaip pi3k-gama inhibitoriai
AR107293A1 (es) 2016-01-05 2018-04-18 Incyte Corp COMPUESTOS DE PIRIDINA Y PIRIDIMINA COMO INHIBIDORES DE PI3K-g
EP3436074B1 (en) * 2016-03-31 2020-06-10 Romark Laboratories, L.C. Thiazolide compounds for treating viral infections
US10138248B2 (en) 2016-06-24 2018-11-27 Incyte Corporation Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors
UY37381A (es) 2016-08-30 2018-03-23 Glaxosmithkline Ip No 2 Ltd Compuestos que inhiben proteasas 3c y 3cl y métodos de uso de los mismos
WO2019079469A1 (en) 2017-10-18 2019-04-25 Incyte Corporation CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED WITH HYDROXY TERTIARY GROUPS AS INHIBITORS OF PI3K-GAMMA
CN111868063B (zh) 2018-01-17 2023-08-01 葛兰素史克知识产权开发有限公司 PI4KIIIβ抑制剂
KR20210046649A (ko) 2018-08-21 2021-04-28 교린 세이야꾸 가부시키 가이샤 이환식 헤테로방향환 유도체
CR20250050A (es) 2018-09-05 2025-03-19 Incyte Corp Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
CN109369545B (zh) * 2018-12-14 2020-04-10 东营曜康医药科技有限公司 2-甲基-5-甲酸吡嗪的合成工艺
AU2020353005A1 (en) 2019-09-23 2022-04-14 Nanjing Zhengxiang Pharmaceuticals Co., Ltd. Phosphodiesterase inhibitors and use
US20230014730A1 (en) 2019-09-23 2023-01-19 Nanjing Zhengxiang Pharmaceuticals Co., Ltd. Phosphodiesterase inhibitors and use
CN115667266A (zh) * 2020-06-01 2023-01-31 豪夫迈·罗氏有限公司 新型咪唑并吡嗪衍生物
CN115667264A (zh) * 2020-06-08 2023-01-31 豪夫迈·罗氏有限公司 新型咪唑并-吡嗪衍生物
CN113929633A (zh) * 2021-10-27 2022-01-14 山东大学 一种法匹拉韦的合成方法及其应用
CN113831255B (zh) * 2021-11-25 2022-03-11 山东诚创蓝海医药科技有限公司 一种2-氨基丙二酰胺的制备方法
CN115489188B (zh) * 2022-10-09 2023-08-29 安徽国风新材料股份有限公司 一种家居保护用聚酯薄膜及其制备方法
EP4623912A1 (en) 2024-03-25 2025-10-01 ETH Zurich A method for defattening a steatotic liver ex vivo
EP4623911A1 (en) 2024-03-25 2025-10-01 ETH Zurich Pi4kb inhibitors for the treatment of fatty liver disease

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2607813B1 (fr) * 1986-12-05 1989-03-31 Montpellier I Universite Alkylamino-8 imidazo (1,2-a) pyrazines et derives, leur preparation et leur application en therapeutique
DE19915178A1 (de) 1999-04-03 2000-10-05 Univ Mainz Johannes Gutenberg Hepatitis C Virus Zellkultursystem
CA2409873C (en) 2000-05-23 2013-01-08 Washington University Hcv variants
WO2002038793A2 (en) 2000-11-07 2002-05-16 Anadys Pharmaceuticals, Inc. Hepatitis c virus constructs characterized by high efficiency replication
CA2430607C (en) 2000-12-22 2009-12-01 Boehringer Ingelheim (Canada) Ltd. Self-replicating rna molecule from hepatitis c virus
EP2050822B1 (en) 2001-01-23 2013-07-31 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Hepatitis C virus replicons and replicon enhanced cells
CA2436487A1 (en) * 2001-01-30 2002-08-08 Cytopia Pty Ltd. Methods of inhibiting kinases
AU2007200401A1 (en) * 2002-09-23 2007-02-22 Schering Corporation Imidazopyrazines as cyclin dependent kinase inhibitors
US7576085B2 (en) * 2002-09-23 2009-08-18 Schering Corporation Imidazopyrazines as cyclin dependent kinase inhibitors
KR20050057520A (ko) * 2002-09-23 2005-06-16 쉐링 코포레이션 사이클린 의존성 키나제 억제제로서의 이미다조피라진
ATE452192T1 (de) 2003-02-13 2010-01-15 Merck & Co Inc Verfahren zur vermittlung von zellkulturreplikationsaktivität an unterschiedliche hepatitis-c-virus-isolate
AR043002A1 (es) 2003-02-18 2005-07-13 Altana Pharma Ag Imidazopirazinas 6-substituidos
US7157460B2 (en) 2003-02-20 2007-01-02 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US7186832B2 (en) * 2003-02-20 2007-03-06 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
CA2628534A1 (en) 2005-11-10 2007-05-18 Schering Corporation Methods for inhibiting protein kinases
AU2006315718B2 (en) * 2005-11-10 2012-10-04 Merck Sharp & Dohme Corp. Imidazopyrazines as protein kinase inhibitors
AU2007338601C1 (en) * 2006-09-05 2014-07-24 Emory University Tyrosine kinase inhibitors for prevention or treatment of infection
WO2008030795A2 (en) 2006-09-05 2008-03-13 Boards Of Regents, The University Of Texas System Compositions and methods for inhibition of tyrosine kinases
WO2008057512A2 (en) 2006-11-08 2008-05-15 Schering Corporation Imidazopyrazines as protein kinase inhibitors
WO2008059373A1 (es) 2006-11-17 2008-05-22 Raqualia Pharma Inc. Vacuna contra la malaria, basada en la subunidad 200l de la proteína msp1 de plasmodium vivax.
US8243049B2 (en) 2006-12-20 2012-08-14 3M Innovative Properties Company Untethered stylus employing low current power converter
GB0716292D0 (en) * 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds

Also Published As

Publication number Publication date
BRPI0815717A2 (pt) 2015-02-10
EP2193131A2 (en) 2010-06-09
AU2008290531A1 (en) 2009-02-26
HK1143810A1 (en) 2011-01-14
US20110166147A1 (en) 2011-07-07
CY1113872T1 (el) 2016-07-27
KR20100081294A (ko) 2010-07-14
ZA201002009B (en) 2010-12-29
SI2193131T1 (sl) 2013-06-28
EP2567960A3 (en) 2013-06-05
EP2193131B1 (en) 2013-01-30
GB0716292D0 (en) 2007-09-26
PL2193131T3 (pl) 2013-07-31
WO2009024585A2 (en) 2009-02-26
WO2009024585A3 (en) 2009-08-06
HRP20130202T1 (hr) 2013-04-30
NZ584108A (en) 2012-06-29
CA2707521A1 (en) 2009-02-26
DK2193131T3 (da) 2013-04-22
ES2404415T3 (es) 2013-05-27
JP2010536825A (ja) 2010-12-02
EP2567960A2 (en) 2013-03-13
US8362018B2 (en) 2013-01-29
PT2193131E (pt) 2013-04-04
CN101835780A (zh) 2010-09-15
CN101835780B (zh) 2013-09-18

Similar Documents

Publication Publication Date Title
MX2010001733A (es) Compustos de imidazo[1,2-a]pirazina para tratamiento de infecciones virales tales como hepatitis.
TN2012000416A1 (en) Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
MX2013003634A (es) Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales.
WO2008127364A3 (en) Antiviral compounds and use thereof
MX2009009473A (es) Compuestos para el tratamiento de hepatitis c.
WO2012018534A3 (en) Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
SG178952A1 (en) Chemical compounds
ZA201002690B (en) N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (hcv) inhibitors
IL182315A0 (en) 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection
WO2010084115A3 (en) Antiviral agents
NZ585226A (en) Inhibitors of human immunodeficiency virus replication
IL196815A0 (en) Hepatitis c virus inhibitors
WO2008021936A3 (en) Hepatitis c virus inhibitors
TN2010000137A1 (en) Spiropyrrolidines and their use against hcv and hiv infection
TN2012000264A1 (en) Hepatitis c virus inhibitors
TN2012000214A1 (en) Hepatitis c virus inhibitors
MX2010009563A (es) Compuestos quimicos con accion antiviral contra virus de dengue y otros flavivirus.
MX2011008045A (es) Inhibidores del virus de la hepatitis c.
MY152971A (en) Hepatitis c virus inhibitors
PH12012501216A1 (en) Hcv combination therapy
TN2015000293A1 (en) Heterocycle-substituted tetracyclic compounds and methods of use thereof for treatment of viral diseases
WO2011150190A3 (en) Hcv inhibitor compounds and methods of use thereof
MX2010001416A (es) Compuesto para el tratamiento de la hepatitis c.
WO2007041632A3 (en) Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection
TW200800993A (en) Organic compounds

Legal Events

Date Code Title Description
FG Grant or registration